This phase II study is evaluating alternative dosing regimens of immunotherapy (belantamab mafodotin) in people with relapsed or refractory multiple myeloma to determine if this improves outcomes and reduces side effects..
This trial is treating patients with relapsed or refractory multiple myeloma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 2, Randomized, Parallel, Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-agent Belantamab Mafodotin (GSK2857916) in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM-14)
Commercial Sponsor
GlaxoSmithKline
Summary
Eligible participants will be randomly allocated to one of five experimental cohorts. Each cohort will receive a different dose level of belantamab mafodotin.
Recruiting Hospitals Read More